ClinicalTrials.Veeva

Menu

Microcephaly Genetic Deficiency in Neural Progenitors (MICROFANC)

A

Assistance Publique - Hôpitaux de Paris

Status

Completed

Conditions

Microcephaly

Study type

Observational

Funder types

Other

Identifiers

NCT01565005
P 100128

Details and patient eligibility

About

The purpose of this study is to:

I. Compare neuroradiological phenotype and cognitive functioning of MCPH patients caused by ASPM mutations already characterized and published (Passemard et al. 2009a) with other MCPH-related patients (patients with MCPH1, WDR62, CDK5RAP2, CEP 152, CENPJ, STIL, or PCNT mutations)

II. Describe the neuro-radiological and cognitive phenotype of microcephalic patients suffering from Fanconi anemia, and compared them to subjects with:

  • Fanconi anemia but normal OFC (head circumference)
  • MCPH patients
  • Healthy control subjects Our hypothesis is that mutations in genes responsible of microcephaly impact differentially cortical brain development and functioning

Full description

Phenotyping study on 2 different cohorts of rare disease affected patients:

  • Group1: MCPH (including different MCPH subtypes)
  • Group2: Fanconi Anemia (with or without microcephaly)

Inclusion criteria:

Common to each group:

  • Age > 3 years
  • Access to french "Social Security"
  • No contraindication for MRI

Group1:

  • Primary microcephaly without gross malformation within or extra nervous central system
  • OFC < -2SD at birth and < -3 SD after age 6months
  • Mutation in one MCPH gene

Group2:

Proven Fanconi Anemia with:

  • Positive chromosome breakage blood test
  • One of the 3 following elements:

FANCD2 positive test Fibroblast sensitivity to mitomycin Mutation in one FANC gene

Control subjects:

  • No antecedent
  • Normal education

Aims:

  1. Description of neurological, neuropsychological and radiological phenotype for each group

  2. Phenotype comparison:

    • groups 1&2
    • group1 or 2 with control subjects
    • different MCPH subtypes within group1
    • with or without microcephaly within group2
  3. Epidemiological data on these rare diseases in our population

Protocol:

Patients from both groups and control subjects will be evaluated in CIC for 1 day ½. They will be examined by a child neurologist and a geneticist. All of them will have cranial MRI (1.5Tesla). Neuropsychological assessment will be performed (Wechsler scales) for patients and control subjects.

Enrollment

98 patients

Sex

All

Ages

3+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients aged ≥ 3 years:

  • Microcephalic phenotype consistent with MCPH (recruitment already done as part of a network GIS-Rare Diseases Institute). MCPH patients have already been selected in the cohort "Robert Debré."
  • Holders of a Fanconi anemia characterized in terms of cytogenetics, enzyme and/or molecular (patients in the cohort "Saint Louis" followed by the KRC rare aplastic anemia)
  • Healthy controls aged ≥ 5 years siblings of patients with Fanconi Anemia

Exclusion criteria

Patients with Fanconi anemia:

  • bone marrow < 3 years
  • Post-transplantation neurological complications
  • developmental, genetic or environmental additional pathology

Trial design

98 participants in 2 patient groups

Microcephaly
Description:
Microcephaly Intellectual abilities Cranial MRI
FANCONI ANEMIA

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems